In a significant shift, COVID-19 treatments that were once provided for free by the federal government will soon enter the private market, accompanied by a substantial price tag. Pfizer, a leading pharmaceutical company, has set the cost for a five-day course of Paxlovid at $1,390. While this marks a transition to a paid model, Americans currently have continued access to the pills without cost. Another COVID-19 treatment, Lagevrio from Merck, is also poised to enter the market, with millions of taxpayer-funded courses of both medications remaining available at various healthcare facilities across the nation.
The initial government deal with Pfizer in 2021 involved a payment of over $5 billion for 10 million courses of Paxlovid. A recent agreement ensures that individuals covered by Medicaid, Medicare, or those without medical insurance will not incur any out-of-pocket costs for Paxlovid until the end of the next year. Furthermore, Pfizer will extend copay assistance for the treatment until 2028. Notably, government entities such as the Department of Veterans Affairs, the Department of Defense, and the Indian Health Service will retain access to Paxlovid from the government's stockpile.
As supplies to pharmacies and healthcare providers become available for order next week, individuals on private insurance may start encountering copays once the government-supplied treatments are depleted. Pfizer expressed its commitment to a seamless commercial transition, emphasizing collaboration with the U.S. government and healthcare stakeholders to ensure widespread and equitable access to Paxlovid.
Paxlovid, in use since 2021, received full approval from the Food and Drug Administration earlier this year for treating adults with COVID-19 who face a heightened risk of hospitalization or death, typically including older adults and those with underlying medical conditions. The anticipated full-year revenue for Paxlovid and Pfizer's COVID-19 vaccine, Comirnaty, is projected to reach around $12.5 billion. This development signifies a pivotal moment as COVID-19 treatments transition from a government-subsidized model to a commercial one.
While Merck has not officially disclosed the list price for its Lagevrio COVID-19 treatment, the pharmaceutical company has communicated its commitment to making the treatment accessible to patients who may face financial barriers. In a statement provided to the Associated Press, Merck affirmed its intention to offer the Lagevrio treatment at no cost to individuals who, without assistance, would encounter challenges affording the product. This underscores the company's dedication to ensuring broader access to essential COVID-19 treatments, aligning with the ongoing efforts to address healthcare equity and affordability. Associated Press reporter Tom Murphy in Indianapolis contributed to this report, providing valuable insights into the evolving landscape of COVID-19 treatments and their accessibility.
In conclusion, the impending entry of COVID-19 treatments, such as Pfizer's Paxlovid and Merck's Lagevrio, into the private market with associated costs marks a significant shift in the landscape of pandemic management. While Pfizer has set a price for its treatment, the government's prior agreements secure continued free access for certain populations, highlighting a transitional period in healthcare financing. Merck, yet to confirm the list price for Lagevrio, has affirmed its commitment to providing the treatment at no cost to patients facing financial constraints. This dual approach reflects the pharmaceutical industry's recognition of the need for accessibility and affordability amid ongoing public health challenges. As these treatments navigate the delicate balance between commercial viability and equitable healthcare provision, they serve as crucial tools in the ongoing battle against the COVID-19 pandemic. The collaborative efforts between pharmaceutical companies, the government, and healthcare stakeholders will play a pivotal role in shaping the future of treatment accessibility and affordability.